Classes
DEA Class; Rx
Common Brand Names; ReoPro
- Antiplatelet Agents, Cardiovascular;
- Glycoprotein IIb/IIIa Inhibitors
Description
Platelet glycoprotein IIb/IIIa receptor antagonist
Adjunctive therapy for preventing cardiac ischemic complications in percutaneous coronary intervention (PCI) or in patients with unresponsive unstable angina
Fab fragment of the chimeric monoclonal antibody 7E3
Indications
Indicated for the Prevention of cardiac ischemic complications in patients undergoing PCI
Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr
Adjunctive therapy during thrombolysis (off-label)
Contraindications
Hypersensitivity
Active internal bleeding
Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance
History of CVA (within 2 years) or CVA with a significant residual neurological deficit
Bleeding diathesis
Administration of oral anticoagulants within seven days unless prothrombin time is ≤1.2 times control
Thrombocytopenia (< 100,000 cells/μL)
Recent (within six weeks) major surgery or trauma
Intracranial neoplasm, arteriovenous malformation, or aneurysm
Severe uncontrolled hypertension
Presumed or documented history of vasculitis
Adverse Effects
- Bleeding, minor (70-82%)
- Bleeding, major (17-21%)
- Hypotension (14-21%)
- Back pain (17.6%)
- Nausea (13.6%)
- Chest pain (11.4%)
- Vomiting (7-11%)
- Headache (6%)
- Thrombocytopenia (2-6%)
- Bradycardia (5%)
- Injection site pain (3.6%)
- Extremity pain (3.5%)
- Abdominal pain (3%)
- UTI (2%)
- Dizziness (1.8%)
- Peripheral edema (1.6%)
- Anemia (1.2%)
- Diarrhea (1%)
- Hypoesthesia (1%)
Warnings
Intended for use with aspirin and heparin, and has only been studied in that setting
Allergic reactions, some of which were anaphylaxis (sometimes fatal), reported rarely in patients receiving therapy; patients with allergic reactions should receive appropriate treatment; treatment of anaphylaxis should include immediate discontinuation of therapy and initiation of resuscitative measures
In the event of serious uncontrolled bleeding or need for emergency surgery, therapy should be discontinued; if platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions
Pregnancy and Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk; use caution
Maximum Dosage
2,000 mg/day PO.
2,000 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Abciximab
injectable solution
- 2mg/mL
